Corcept Therapeutics Incorporated (CORT): Business Model Canvas [Apr-2026 Updated]

You're looking at Corcept Therapeutics Incorporated (CORT), and honestly, the model is straightforward but hinges on a massive near-term catalyst. As an analyst who's seen this play out many times, the core engine here is the current cash cow, Korlym, funding the next big bet, relacorilant, which has a critical PDUFA date looming on December 30, 2025. With a strong balance sheet showing $515.0 million in cash as of June 30, 2025, and projected 2025 revenue between $800 million and $850 million, the runway is solid, but the value inflection point is clearly tied to that next approval. Dive into the full Business Model Canvas below to see exactly how this specialized biotech firm manages its high-margin product sales against heavy R&D spending to push its next-generation cortisol modulator through the regulatory gauntlet.

Corcept Therapeutics Incorporated (CORT) - Canvas Business Model: Key Partnerships

When you're managing a commercial-stage company like Corcept Therapeutics Incorporated, the partners you choose are critical, especially as you prepare for major product launches. The success of Korlym and the anticipated launch of relacorilant hinges on these external relationships.

Specialty pharmacy vendors for exclusive drug distribution and patient support

Distribution relies heavily on specialty pharmacy vendors who handle the complex logistics for drugs like Korlym. Honestly, capacity has been a near-term risk; demand outpaced the previous vendor's ability to supply earlier this year. You saw this reflected in the Q3 2025 revenue of $207.6 million, which management noted didn't fully capture the surge in demand. To address this, Corcept Therapeutics added a new specialty pharmacy on October 1. They plan to onboard others in the coming months, which should help meet the demand driving the revised full-year 2025 revenue guidance of $800 - $850 million. The previous exclusive vendor, Optime Care, held the agreement until at least March 31, 2024, for Korlym distribution.

Academic and clinical research institutions for ongoing clinical trials (e.g., ROSELLA, BELLA)

The pipeline development, particularly for relacorilant, is deeply intertwined with major academic and clinical research groups globally. These collaborations are essential for generating the data needed for regulatory submissions. For instance, the pivotal Phase 3 ROSELLA trial, which enrolled 381 patients, involved a broad international network.

Here's a look at the key trial partnerships and data points as of late 2025:

The success in ROSELLA, where relacorilant plus nab-paclitaxel showed a 30 percent reduction in risk of disease progression (HR: 0.70; p-value: 0.0076), is a direct result of these research partnerships.

Contract Manufacturing Organizations (CMOs) for drug production and supply chain management

While specific CMO names aren't public in the latest filings, the need for robust manufacturing partnerships is clear given the commercial trajectory. Corcept Therapeutics is preparing for the potential launches of relacorilant for hypercortisolism (PDUFA date December 30, 2025) and ovarian cancer (PDUFA date July 11, 2026). The company's Q3 2025 operating expenses were $197.4 million, partly due to increased spending to prepare for these launches. Securing reliable, scalable manufacturing capacity through CMOs is a necessary step to support the projected revenue growth, especially since Korlym sales for the first nine months of 2025 reached $559.3 million.

Regulatory bodies like the FDA and EMA for product approvals

Regulatory bodies act as critical gatekeepers, and Corcept Therapeutics has several key dates on the calendar. The company is actively engaged with the FDA regarding two major applications for relacorilant.

Key regulatory milestones include:

• The FDA accepted the New Drug Application (NDA) for relacorilant in hypercortisolism on March 3, 2025.
• The Prescription Drug User Fee Act (PDUFA) date for the hypercortisolism NDA is December 30, 2025.
• The PDUFA date for the NDA for relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer is July 11, 2026.
• Corcept Therapeutics also submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for the ovarian cancer indication, with approval expected by the end of 2026.

The company's cash and investments stood at $524.2 million as of September 30, 2025, providing a solid base to manage these regulatory processes.

Finance: draft 13-week cash view by Friday.

Corcept Therapeutics Incorporated (CORT) - Canvas Business Model: Key Activities

You're looking at the core engine driving Corcept Therapeutics Incorporated's value right now, which is heavily weighted toward regulatory milestones and pipeline execution. The company's key activities are focused on maximizing the current product while pushing two major New Drug Applications (NDAs) through the FDA pipeline.

Research and development (R&D) of selective cortisol modulators.

Corcept Therapeutics Incorporated is actively funding its R&D, which is a primary driver of operating expenses. For the third quarter of 2025, R&D spending was reported at $68.8 million. This spending supports the ongoing discovery of proprietary selective cortisol modulators, a focus for the company for over 25 years.

Commercialization and marketing of Korlym for Cushing's syndrome.

The commercial team is focused on driving volume for Korlym, the first medication approved by the U.S. Food and Drug Administration for endogenous hypercortisolism, introduced in February 2012. The third quarter of 2025 saw a 42.5% increase in tablets shipped compared to the third quarter of 2024. To support this growth, Corcept Therapeutics Incorporated is executing a pharmacy transition, planning to add more specialty pharmacies to meet demand, following earlier capacity constraints.

Managing the relacorilant New Drug Application (NDA) process with the FDA.

A critical activity is managing the regulatory pathway for relacorilant. The NDA for relacorilant to treat hypercortisolism has a Prescription Drug User Fee Act (PDUFA) date set for December 30, 2025. Furthermore, the NDA for relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer has a PDUFA date scheduled for July 11, 2026. The company believes both deadlines will be met.

Defending intellectual property and managing patent litigation.

Corcept Therapeutics Incorporated is involved in managing patent litigation issues that could affect future operations. Relacorilant itself is proprietary and protected by composition of matter, method of use, and other patents.

Clinical trial execution for pipeline candidates in oncology and endocrinology.

Execution across the pipeline involves several key trials where data readouts are imminent or ongoing. The company is expanding oncology programs and advancing trials in metabolic diseases. Here are some key operational and financial metrics as of the third quarter of 2025:

The clinical execution includes several important studies:

• MOMENTUM trial enrollment continues in 1,000-patient cohort studying hypercortisolism in resistant hypertension; results expected by early 2026.
• Final overall survival results from the pivotal ROSELLA trial are expected by early 2026.
• Results from the BELLA trial in advanced ovarian cancer should be available by the end of 2026.
• Results from MONARCH, the Phase 2b trial in patients with metabolic dysfunction-associated steatohepatitis (MASH), are also expected by the end of 2026.
• The company is about to start a Phase 3 trial of dazucorilant in patients with ALS.
• New studies include Phase 2 trials of relacorilant in combination with chemotherapy.
• A Phase 1b trial of nenocorilant in combination with immunotherapy in solid tumors is set to begin.

The company is definitely investing heavily in these future assets, as shown by the Q3 2025 operating expenses reaching $197.4 million.

Corcept Therapeutics Incorporated (CORT) - Canvas Business Model: Key Resources

You're looking at the core assets Corcept Therapeutics Incorporated (CORT) relies on to drive its business, and honestly, it's a mix of deep science and hard cash. The foundation is definitely their intellectual property.

First up, you have the proprietary portfolio of over 1,000 selective cortisol modulators. That's a huge library of novel molecules they've discovered over their history, all designed to regulate cortisol activity at the glucocorticoid receptor (GR). This depth of chemical space is a massive barrier to entry for competitors, showing defintely a long-term commitment to this specific therapeutic area.

Then there's Korlym (mifepristone) drug approval and associated patents. While the original composition of matter patent on mifepristone has expired, Corcept Therapeutics Incorporated protects Korlym through a thicket of method of use patents. These U.S. method of use patents, directed to treating hypercortisolism, have expiration dates ranging from 2028 to 2038. Furthermore, patents on their next-generation selective cortisol modulators extend protection out to 2041. One specific patent covering the administration of Korlym with food is set to expire in November 2032. It's this patent strategy that keeps generic competition at bay for now, with an estimated generic launch date around August 22, 2038.

The near-term value driver is clearly the lead pipeline candidate, relacorilant. You need to watch two key dates here: the Prescription Drug User Fee Act (PDUFA) date for hypercortisolism is set for December 30, 2025. If that goes well, the PDUFA date for the platinum-resistant ovarian cancer indication is July 11, 2026. Success on these fronts unlocks significant future revenue streams, potentially reaching $3-$5 billion in peak sales for the hypercortisolism market over the next 3-5 years, as some analysts project.

To fund all this development and maintain operations while awaiting these critical decisions, Corcept Therapeutics Incorporated sits on a strong balance sheet. Here's the quick math on their financial position as of the second quarter end:

Finally, the company's success hinges on its specialized scientific and regulatory talent. This isn't just about having smart people; it's about having a deep, institutional knowledge base built over time. Corcept Therapeutics Incorporated has been focused on cortisol modulation for over 25 years, which translates directly into the expertise needed to navigate complex FDA submissions like the one for relacorilant.

You can summarize the core tangible assets like this:

• Portfolio of over 1,000 proprietary selective cortisol modulators.
• Korlym method-of-use patents expiring between 2028 and 2038.
• Relacorilant NDA PDUFA date: December 30, 2025.
• Cash and investments balance: $515.0 million (June 30, 2025).
• Deep expertise built over 25+ years in cortisol modulation.

Finance: draft 13-week cash view by Friday.

Corcept Therapeutics Incorporated (CORT) - Canvas Business Model: Value Propositions

Corcept Therapeutics Incorporated's value proposition centers on delivering first-in-class or best-in-class therapies by modulating the effects of cortisol, targeting serious, often rare, diseases.

Korlym, the company's sole marketed product, represents a foundational value pillar. It is the first FDA-approved medication for endogenous hypercortisolism, a severe endocrine disorder. The commercial performance reflects its unique market position, with first nine months of 2025 sales reaching $559.3 million, up around 13.4% year over year. Management's full-year 2025 revenue guidance has been revised to the $800-$850 million range, following strong Q3 2025 revenue of $207.6 million.

The pipeline is anchored by relacorilant, positioned as a next-generation, selective cortisol modulator. This asset targets both endocrinologic and oncologic disorders, offering a potentially improved safety profile over existing treatments. For endogenous hypercortisolism, the FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of Dec. 30, 2025. The global market for endogenous hypercortisolism is estimated at $5.89 billion in 2025.

Relacorilant's value extends into oncology, specifically for platinum-resistant ovarian cancer (PROC). Data from the Phase III ROSELLA trial showed that adding relacorilant to nab-paclitaxel resulted in a 30% reduction in the risk of progression (HR 0.70) and a 31% reduction in the risk of death (HR 0.69) compared to monotherapy. The FDA accepted the New Drug Application (NDA) for this indication, with a PDUFA date of July 11, 2026. Analysts project relacorilant's total global sales could reach $3.38bn by 2031.

Corcept Therapeutics Incorporated's focus is on treatment for rare, severe endocrinologic and oncologic disorders where current therapeutic options are limited or inadequate. The company is also developing relacorilant for other indications, including prostate cancer.

The pricing power derived from these unique, often orphan, indications is reflected in the company's exceptional profitability structure, as evidenced by the high gross margin.

The value proposition is further supported by the company's operational focus:

• Korlym: Sole-marketed drug for Cushing's syndrome.
• Relacorilant: Selective glucocorticoid receptor antagonist.
• Orphan Drug Designation: Granted in U.S. and EU for hypercortisolism.
• Pipeline Expansion: Studies in ovarian, endometrial, cervical, and pancreatic cancers.

The company's market capitalization as of early December 2025 was $8.83 billion.

Corcept Therapeutics Incorporated (CORT) - Canvas Business Model: Customer Relationships

High-touch, specialized patient support programs for rare disease management are central to Corcept Therapeutics Incorporated's commercial structure for Korlym. The company ensures deep patient engagement through its Corcept Cares Patient Advocate Program. Over 85% of patients shipped medication from the SPARK specialty pharmacy participated in this program.

Dedicated patient access services are managed through the Support Program for Access and Reimbursement for Korlym (SPARK), which is the sole commercial distribution channel for Korlym tablets. This dedicated coordination helps navigate insurance and affordability hurdles. As a result of these efforts, over 90% of patients who received medication from SPARK paid $25 or less for a 30-day supply.

The investment in these relationships is substantial, as evidenced by the company's operating expenses. Third quarter 2025 operating expenses were $197.4 million, which included spending to prepare for the launches of relacorilant for hypercortisolism and platinum-resistant ovarian cancer.

Direct engagement with endocrinologists and oncologists is being aggressively scaled up to address the underdiagnosed patient population. Only an estimated 10%-15% of hypercortisolism patients are currently diagnosed. To capture this opportunity, Corcept Therapeutics Incorporated is expanding its clinical specialist team from 125 to a target of 175 by the end of 2025. Analysts project each new sales representative could generate $2-$3 million in annual revenue.

Medical information and support for key prescribers are critical, especially as Corcept Therapeutics Incorporated expands its oncology focus with relacorilant. The company supports physicians with educational materials to help them identify and manage hypercortisolism, alongside peer-to-peer programs featuring leading experts. The clinical data supporting the oncology push, such as the ROSELLA trial in platinum-resistant ovarian cancer, involved 381 patients.

For patients who may not qualify for clinical trials or need access to investigational medications, Corcept Therapeutics Incorporated offers compassionate use (expanded access). Physicians can initiate this process by contacting the company directly. The company held $524.2 million in cash and investments as of September 30, 2025, supporting these extensive commercial and medical affairs activities.

• Physicians request investigational access by contacting Corcept Therapeutics Incorporated at 650-327-3270 or emailing access@corcept.com.
• The company is preparing for the launch of relacorilant, with an NDA submission for ovarian cancer expected by Q3 2025.
• Corcept Therapeutics Incorporated is focused on meeting increasing demand, having modified its 2025 revenue guidance to $800 - $850 million.

Corcept Therapeutics Incorporated (CORT) - Canvas Business Model: Channels

You're looking at how Corcept Therapeutics Incorporated gets its value proposition-medications like Korlym-to the customer base, and the data shows a clear pivot toward expansion in late 2025.

Exclusive network of specialty pharmacy vendors for dispensing Korlym.

Corcept Therapeutics Incorporated has been actively managing its specialty pharmacy distribution for Korlym. The company experienced fulfillment capacity constraints earlier in 2025 due to its previous vendor, Optime Care, which had been the exclusive provider since 2017.

The channel strategy shifted significantly in the third quarter of 2025:

• The company delivered a notice of termination to Optime Care on October 10, 2025, with the agreement ending effective January 8, 2026.
• Corcept Therapeutics Incorporated added a new specialty pharmacy on October 1st.
• The company stated plans to add others in the coming months following the Q3 2025 update.

This operational change is intended to meet the surge in demand, which saw Korlym generate $559.3 million in sales for the first nine months of 2025. The full-year 2025 revenue guidance was modified to the range of $800 - $850 million.

Direct sales force targeting endocrinology and oncology specialists.

Corcept Therapeutics Incorporated is aggressively scaling its commercial presence to capture more of the underdiagnosed hypercortisolism patient population and to prepare for potential oncology indications.

The sales force expansion is a key metric here:

This growth is specifically aimed at increasing education among endocrinologists, as only an estimated 10%-15% of hypercortisolism patients are currently diagnosed. Furthermore, the sales force build-out supports the oncology push, targeting specialists for indications like platinum-resistant ovarian cancer, where the potential market is estimated at $1 billion in annual sales if relacorilant is approved.

Medical science liaisons (MSLs) for scientific exchange with key opinion leaders.

While a specific headcount for the Medical Science Liaison (MSL) team isn't explicitly stated, Corcept Therapeutics Incorporated is actively adding personnel across its commercial and development functions to support its expanding pipeline, which includes relacorilant for hypercortisolism (PDUFA date December 30, 2025) and oncology indications. The company has a stated need to 'continue to add talented, experienced personnel to our endocrine, oncology and emerging markets businesses'.

Clinical trial sites for patient recruitment and drug delivery.

The channel for clinical development involves a global infrastructure of ongoing trials across multiple therapeutic areas, which necessitates engagement with numerous investigator sites. Corcept Therapeutics Incorporated is running several key studies that define this channel:

• Hypercortisolism: Trials include GRACE, GRADIENT, CATALYST (which found 23.8% prevalence in difficult-to-control diabetes patients in Phase 1), and MOMENTUM.
• Oncology: The pivotal Phase 3 ROSELLA trial in platinum-resistant ovarian cancer enrolled 381 women. New studies are expanding into endometrial, cervical, and pancreatic cancers.
• Other Areas: Trials are ongoing or planned for ALS (DAZALS) and MASH/NASH.

The company is focused on managing these clinical trials effectively as part of its growth strategy.

Corcept Therapeutics Incorporated (CORT) - Canvas Business Model: Customer Segments

You're looking at the specific groups Corcept Therapeutics Incorporated (CORT) targets with its cortisol modulation platform, which is a mix of established revenue drivers and high-potential pipeline expansion areas as of late 2025.

The core customer segment remains patients with endogenous hypercortisolism, also known as Cushing's syndrome. This is currently served by Korlym (mifepristone), which is indicated for treating hyperglycemia secondary to this condition in adult patients with type 2 diabetes or glucose intolerance for whom surgery failed or who are not candidates for surgery. The company is awaiting a decision on its next-generation selective cortisol modulator, relacorilant, for this indication, with the FDA PDUFA date set for December 30, 2025.

The financial performance tied to this segment shows strong momentum. For the first nine months of 2025, Korlym recorded sales of $559.3 million, representing an increase of around 13.4% year over year. Corcept Therapeutics has a revised 2025 revenue guidance range of $800 - $850 million, though prior guidance was as high as $900-950 million. The total Cushing's syndrome diagnostics and therapeutics market is valued at $383.04 million in 2025.

Here's a breakdown of the key patient populations and the associated market scope:

The potential future segment of oncologists treating PROC is supported by strong Phase 3 ROSELLA trial data. The combination therapy showed a median Progression-Free Survival (PFS-BICR) of 6.5 months compared to 5.5 months for chemotherapy alone, a 30% reduction in progression risk. An interim look at Overall Survival (OS) showed a median of 16 months versus 11.5 months for the control arm. The PDUFA date for relacorilant in this indication is July 11, 2026.

For the potential future indication in T2D, the CATALYST study provided concrete numbers on the addressable patient pool. You should note that:

• 23.8% of patients with difficult-to-control T2D (HbA1c >7.5%) had hypercortisolism.
• Korlym treatment led to a 1.47% reduction in HbA1c versus 0.15% for placebo in this group.
• This T2D sub-segment is estimated to represent a $2.8 billion market opportunity.

The specialists driving the current business are physicians in endocrinology and rare metabolic disorders. Corcept Therapeutics Incorporated has been actively building out its commercial reach to capture this market:

• Sales force expanded to 125 specialists, with a goal of reaching 175 by year-end 2025.
• The company reported a record rate of new prescribers over five consecutive quarters as of Q1 2025.

Looking further out, Corcept Therapeutics projects that relacorilant, once approved across its pipeline indications, could achieve peak annual revenues of $3 billion to $5 billion in the hypercortisolism market alone within three to five years. The company also maintains a strong cash position, reported at $515 million at the end of Q2 2025, which supports the commercial and clinical expansion targeting these segments.

Corcept Therapeutics Incorporated (CORT) - Canvas Business Model: Cost Structure

You're looking at the expense side of Corcept Therapeutics Incorporated's business, which is heavily weighted toward scaling commercial operations and advancing the pipeline. The total operating expenses for the second quarter of 2025 hit $\mathbf{\$167.8 \text{ million}}$, a noticeable increase from $\mathbf{\$128.2 \text{ million}}$ in the same period last year.

Here's a quick look at some of the key financial figures that define the cost base as of late 2025:

The push for commercialization is clearly visible in the Selling, General, and Administrative (SG&A) line item. This expense category surged $\mathbf{55.3\%}$ year-over-year in Q2 2025, reaching $\mathbf{\$103.9 \text{ million}}$. This reflects the scaling of the commercial organization, including the growth in clinical specialists, which was reported to be around $\mathbf{145}$ versus approximately $\mathbf{60}$ in 2024, with a target of $\mathbf{175}$ by year-end. That rapid scaling compresses operational leverage, as this SG&A growth substantially outpaced the $\mathbf{18.7\%}$ year-over-year revenue growth in the quarter.

Heavy investment in Research and Development (R&D) remains a core cost driver, underpinning pipeline expansion. While R&D is bundled into the total operating expenses, the balance sheet shows accrued research and development expenses stood at $\mathbf{\$28,322 \text{ thousand}}$ as of September 30, 2025. This spending supports the New Drug Applications (NDAs) in progress for relacorilant in hypercortisolism (PDUFA December 30, 2025) and platinum-resistant ovarian cancer.

Costs associated with patent defense and litigation represent a defintely persistent risk. Corcept Therapeutics Incorporated is currently involved in an appeal of the Teva Pharmaceuticals USA, Inc. patent litigation, which stems from Teva's Abbreviated New Drug Application (ANDA) filing for a generic version of Korlym. The company noted in its February 2025 10-K that such litigation is costly and diverts management's attention from productive efforts.

Manufacturing costs for Korlym are relatively low compared to the revenue generated, which supports a high gross margin profile, though this is being challenged by generic entry. The authorized generic (AG) version of Korlym now accounts for approximately $\text{two-thirds}$ of the business, coming in at an average discount of about $\mathbf{30\%}$ to Korlym's list price. Once a product receives FDA approval, manufacturing costs are capitalized to inventory, using the specific identification method for cost of inventory sold.

You should monitor the following areas closely:

• SG&A spending relative to revenue growth to assess operating leverage.
• The timing and outcome of the December 30, 2025, PDUFA date for relacorilant.
• Any updates on the ongoing appeal in the Teva patent litigation.
• The expected contribution from the second specialty pharmacy coming online in Q4 2025.

Corcept Therapeutics Incorporated (CORT) - Canvas Business Model: Revenue Streams

Corcept Therapeutics Incorporated's revenue streams are currently concentrated but poised for significant diversification, primarily driven by the continued commercial performance of its sole marketed product and the anticipated regulatory approval of its lead pipeline candidate.

Product sales from Korlym for Cushing's syndrome remain the bedrock of the current revenue base. This drug, approved for hypercortisolism, is generating substantial top-line results, even while facing operational hurdles related to specialty pharmacy fulfillment earlier in the year. The momentum in the hypercortisolism segment is strong, marked by a record number of new prescriptions for Korlym in the third quarter of 2025.

For the full-year 2025, Corcept Therapeutics Incorporated has set its total revenue guidance in the range between $800 million and $850 million. This reflects a recent modification from a higher initial projection, attributed to capacity constraints with a previous specialty pharmacy vendor, which the company began addressing with new partnerships starting October 1st.

Here's a quick look at the recent financial performance grounding that guidance:

The company is actively investing to support future growth, with third-quarter 2025 operating expenses reaching $197.4 million, up from $135.9 million in the same period last year, driven by increased spending for relacorilant launch preparations across its indications.

Potential milestone payments or royalties from future partnerships are not the primary current revenue driver, but they represent a secondary, non-guaranteed stream tied to the company's broader development efforts. Corcept Therapeutics Incorporated is expanding its oncology development programs, including new studies in earlier-stage ovarian, endometrial, cervical, and pancreatic cancers, which could lead to future collaboration revenue.

The most significant potential shift in the revenue profile comes from future product sales from relacorilant upon regulatory approval. This next-generation selective cortisol modulator has two key regulatory catalysts:

• NDA for hypercortisolism (Cushing's syndrome) with a Prescription Drug User Fee Act (PDUFA) date of December 30, 2025.
• NDA for platinum-resistant ovarian cancer with a PDUFA date of July 11, 2026.

Management projects that relacorilant in the hypercortisolism market alone has the potential to generate peak sales of $3 billion to $5 billion over the next three to five years, which would substantially diversify the revenue base away from Korlym.